# Star Therapeutics

> Antibody developer rebuilding its pipeline after the sale of Vega Therapeutics.

## Why it is interesting

The Vega exit provides evidence of the team's ability to advance a development asset to a pharmaceutical acquisition. Investors are backing another pipeline, but its undisclosed preclinical programs still face clinical, regulatory and capital risks.

## Profile

- **Latest funding:** Private financing (lettered series undisclosed) — $200M (October 23, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $200M
- **Stage:** other
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-24
- **Latest funding investors:** OrbiMed, Janus Henderson Investors, Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital

## Key facts

- $200M private financing announced October 23, 2026.
- OrbiMed and Janus Henderson Investors co-led the financing.
- Vega sale proceeds and conditional milestones are separate from the new financing.

## Funding history

- Private financing (lettered series undisclosed) · $200M · October 23, 2026
  Source: https://star-therapeutics.com/star-therapeutics-announces-200-million-private-financing-to-advance-pipeline-of-best-in-disease-therapies-2/

## Investors in our directory

- https://venturecapitaltracker.com/fund/orbimed
- https://venturecapitaltracker.com/fund/janus-henderson-investors
- https://venturecapitaltracker.com/fund/ra-capital-management

## Related articles

- https://venturecapitaltracker.com/star-therapeutics-200m-private-financing-vega-sale

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 24, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/star-therapeutics